A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus

General Information

Summary The purpose of the study is to evaluate the safety of GRNOPC1 administered at a single time-point between 7 and 14 days post injury, inclusive, to patients with neurologically complete spinal cord injuries (SCI).
Clinical trials phase Phases 1/2
Start date (estimated) 2014-09-01
End date (estimated) 2021-01-31
Clinical feature
Label Diabetes Mellitus, Type 1
Link http://purl.obolibrary.org/obo/OMIT_0005198

Administrative Information

NCT Number NCT02239354
Other study identifiers
Name VC01-101
Source weblink http://clinicaltrials.gov/ct2/show/NCT02239354
Regulatory body approval
Name Food and Drug Administration (FDA)
Country
United States
Public contact
Email info@viacyte.com
Country
Sponsors ViaCyte
Collaborators

Cell Line

Stem cell lines obtained from

Recruitment

Recruitment Status Active, not recruiting
Estimated number of participants 69